EBITDA Margin % is calculated as EBITDA divided by its Revenue. Everest Medicines's EBITDA for the
six
months ended in Dec. 2025 was HK$-285 Mil. Everest Medicines's Revenue for the
six
months ended in Dec. 2025 was HK$1,393 Mil. Therefore, Everest Medicines's EBITDA margin for the quarter that ended in Dec. 2025 was -20.47%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Everest Medicines EBITDA Margin % Related Terms
Everest Medicines EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Everest Medicines's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01952 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Everest Medicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Everest Medicines's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines (HKSE:01952) has a EBITDA Margin % of -20.47% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Everest Medicines and its competitors. According to the industry distribution chart, Everest Medicines ranks #395 out of 939 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Everest Medicines' EBITDA Margin % too high?
Everest Medicines' current EBITDA Margin % is -20.47%. Based on the distribution chart, Everest Medicines ranks #395 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Everest Medicines has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #395 out of 939 companies for EBITDA Margin %. This puts Everest Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Everest Medicines and its competitors. Everest Medicines's current EBITDA Margin % is -20.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$290.08, compared to a current price of HK$27.80 — trading 90.4% below its estimated fair value. The current EBITDA Margin % is -20.47%. Everest Medicines' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current EBITDA Margin % is -20.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (HKSE:01952) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of HK$27.80 is trading 90.4% below its estimated GF Value™ of HK$290.08.
GuruFocus considers Everest Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01952:
EBITDA Margin %: -20.47%
GF Value™: HK$290.08 vs. price of HK$27.80 (90.4% below fair value)
No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
43GF Score
Get the complete analysis for HKSE:01952
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01952 has been successfully added to your 
